What’s bad for Merck and Schering-Plough may be good for Abbott Laboratories. Yesterday’s downbeat discussion about Vytorin at a meeting of caridologists may lead doctors to look farther for alternative cholesterol treatments when statins aren’t getting the job done. The search may lead them to Abbott.
Abbott markets niacin-based drugs called Niaspan and SimCor (a combination [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment